

DIALOG(R) File 351:Derwent WPI

(c) 2000 Derwent Info Ltd. All rts. reserv.

010229922

WPI Acc No: 1995-131179/199517

Related WPI Acc No: 1990-178822; 1990-245977; 1991-140227; 1992-090221;
1992-097185; 1993-152462; 1996-223439; 1997-020465; 1999-080477;
2000-052540

XRAM Acc No: C95-060552

Admin. of a functional retinoblastoma polypeptide or protein - used to prevent and inhibit prim. and sec. retinoblastoma-linked cancers

Patent Assignee: CANJI INC (CANJ-N); UNIV CALIFORNIA (REGC)

Inventor: GOODRICH D W; JOHNSON D; LEE E Y P; LEE W; SHEPARD H M; WANG N P;
LEE E Y

Number of Countries: 048 Number of Patents: 005

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9507708	A2	19950323	WO 94US10357	A	19940913	199517 B
AU 9478349	A	19950403	AU 9478349	A	19940913	199529
ZA 9407065	A	19950726	ZA 947065	A	19940913	199535
WO 9507708	A3	19950608				199616
IL 110954	A	19991222	IL 110954	A	19940913	200008

Priority Applications (No Type Date): US 93121108 A 19930913

Cited Patents: 4.Jnl.Ref; EP 259031; EP 529160; WO 8906703; WO 9222640

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

WO 9507708	A2	E	163	A61K-038/17	
------------	----	---	-----	-------------	--

Designated States (National): AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ
LK LV MG MN MW NO NZ PL RO RU SD SK UA UZ VN

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL
OA PT SE

AU 9478349	A		A61K-038/17	Based on patent WO 9507708
------------	---	--	-------------	----------------------------

ZA 9407065	A	166	A61K-000/00	
------------	---	-----	-------------	--

IL 110954	A		A61K-039/395	
-----------	---	--	--------------	--

Abstract (Basic): WO 9507708 A

The prevention and inhibition of the proliferation of a pathologically proliferating cell which is the result of the absence or a sub-necessary amt. of a functional retinoblastoma (RB) polypeptide or protein in the cell, comprises contacting the cell with RB polypeptide or protein.

USE - The admin. of functional RB polypeptide is used to treat or prevent a cancer which is the result of a pathological proliferation of cells. The admin. of functional RB protein is used to prevent or treat a pathology in a subject caused by the absence of or a sub-necessary amt. of functional RB protein or polypeptide. Retinal, prostate, psoriatic, thyroid, breast, colon, lung, sarcoma, leukaemia and lymphoma cells can be targetted (all claimed). The RB prod. can be used to control and reversibly arrest the cell cycle in organisms and to suppress cancer. It may be used in combination with other therapeutic methods to arrest tumourigenesis. The protein prod. may also be used to elucidate gene function. The compsn. is administered either intravenously, intratumourally, orally or intraperitoneally.

ADVANTAGE - The method reduces the need for conventional radiation and chemotherapy and therefore insult to the organism is reduced. The compsn. itself possesses little or no toxic effects on healthy cells. In addn., the compsn. is relatively inexpensive and readily obtainable.

Dwg.0/0

Title Terms: ADMINISTER; FUNCTION; POLYPEPTIDE; PROTEIN; PREVENT; INHIBIT;
PRIMARY; SEC; LINK; CANCER

Derwent Class: B04; D16

International Patent Class (Main): A61K-000/00; A61K-038/17; A61K-039/395

International Patent Class (Additional): C07K-016/30

File Segment: CPI

Manual Codes (CPI/A-N): B04-N02; B14-H01; D05-H08

Chemical Fragment Codes (M1):

01 M423 M781 M903 P631 P632 P633 Q233 V752 V901 V902